The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic Innovation
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Liver cancer, predominantly hepatocellular carcinoma (HCC), represents a major global health challenge due to its rising incidence and high mortality rates. This review provides a comprehensive overview of liver cancer pathogenesis, emphasizing the complex interplay of viral infections, metabolic disorders, and genetic alterations driving tumor development. We detail the classification of primary liver cancers and highlight the distinctive molecular and clinical features of HCC and intrahepatic cholangiocarcinoma. Advances in research have led to improved understanding of tumor biology and immune microenvironment, fostering the emergence of targeted therapies and immunotherapies. From the historic reliance on surgical resection and sorafenib to the recent approval of immunotherapy combinations such as atezolizumab plus bevacizumab, therapeutic strategies have evolved substantially, offering improved patient outcomes. Despite these advances, challenges remain in early diagnosis, treatment resistance, and biomarker development. Future directions focus on personalized medicine, novel combination therapies, and global accessibility to enhance survival and quality of life for liver cancer patients. This review synthesizes current knowledge and future perspectives, aiming to inform ongoing efforts to combat this formidable malignancy.